Avecia

Avecia, a part of Nitto Denko Inc.,[1] is a private biotechnology company focused on the development and manufacture of novel medicines using biotechnology techniques. Avecia operates as a contract manufacturing organization (CMO), specializing in oligonucleotide production.[2]

Avecia has two US FDA-audited facilities, one near Boston, MA, and the second in Cincinnati, OH. The combined capacity of these two sites allows Avecia to handle oligonucleotide programs from the pre-clinical through commercial stages. In 2016 Avecia acquired the assets of Irvine Pharmaceutical Services and Avrio Biopharmaceuticals.[2]

It was named as one of the top companies in Oligonucleotide Synthesis industry in January 2019.[3]

References
  1. http://www.nitto.com www.nitto.com
  2. "Nitto Denko Avecia Inc. Acquires the Businesses of Irvine Pharmaceutical Services & Avrio Biopharmaceuticals". Business Wire. 11 October 2016. Retrieved 8 February 2018.
  3. "Oligonucleotide Synthesis Market by 2023: Top Players Like GE Healthcare, Nitto Denko Avecia, Genscript, Genedesign, Bio-Synthesis, ATDBio - Press Release - Digital Journal". www.digitaljournal.com. Retrieved 2019-02-20.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.